Sorafenib for advanced and refractory desmoid tumors. N Engl J Med 2018; 379: 2417-2428.

Published: 22nd March 2019

Authors: Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA et al.

Conclusion

Eight-seven patients with symptomatic or recurrent desmoids were included. Sorafenib improved 2-year progression-free survival from 36 to 81 per cent; hazard ratio 0.13, 95 per cent confidence interval 0.05 to 0.31, P<0.001.

Pubmed Link

Your comments

0 Comments